Triamcinalone
Cutaneous T-cell Lymphoma Stage I
Rochester Skin Lymphoma Medical Group, PLLCPhase 2Dormant
B
57/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 42/ 100
- Competitive Position
- 95/ 100
Competitive context
1 Active assets in the Cutaneous T-cell Lymphoma Stage I cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Mechlorethamine Rochester Skin Lymphoma Medical Group, PLLC | Phase 2 | B |
Vorinostat University of Washington | Phase 2 | CCC |
Fenretinide SciTech Development, Inc. | Phase 1 | CC |
Same molecule, other indications
Triamcinalone is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →